All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Liver cancer is one of the most common and fatal malignant tumors, with 5-year survival rate estimated at 20% - 30%. According to GLOBOCAN, around 782,000 people were estimated to die of the disease in 2018, making it the fourth leading cause of cancer death worldwide \[[@pone.0231466.ref001]\]. In recent years, the incidence of primary liver cancer has risen dramatically, and hepatocellular carcinoma (HCC), the predominate pathological type of primary liver cancer, registered the highest and the most rapid rate of increase in the recent period of time \[[@pone.0231466.ref002]\]. Therefore, it is vital to find new drugs and strategies for HCC treatment.

DaHuangWan (DHW), a traditional herbal formula, consists of two herbal ingredients, Coptidis Rhizoma and Aucklandia lappa Decne, with a ratio of 1:1 (w/w) \[[@pone.0231466.ref003]\]. It has been used clinically in Mongolia for many years to treat gastroenterological disorders and HCC. However, there are no well-controlled scientific experiments to verify the validity of DHW prescription, and the underlying mechanism of the drug remains unclear, which greatly limits the clinical application and further optimization of DHW.

Traditional herbs are usually used in combination. Herb pair, a basic unit in multi-herbal formula, consists of two single herbs and usually has better pharmacological effects than using these herbs alone \[[@pone.0231466.ref004]\]. Coptidis Rhizoma (HuangLian) and Aucklandia lappa Decne are commonly used as paired herbal medicine for cancer treatment. According to chinese traditional medical literature, Coptidis Rhizoma is a widely used traditional chinese herb that eliminates 'heat' and 'toxicity'. The anti-cancer effects of Coptidis Rhizoma may be due to these traditional medical properties of Coptidis Rhizoma \[[@pone.0231466.ref005]\]. It has been reported that Coptidis Rhizoma extract and its active ingredient, Berberine, has an anti-tumor effect on various human cancers \[[@pone.0231466.ref005]\]. Coptidis Rhizoma extract inhibits the migration and invasion of HCC cells by down-regulating the RHO/ ROCK signaling pathway \[[@pone.0231466.ref006]\]. Berberine induces death of human hepatoma cells in vitro by down-regulating CD147 \[[@pone.0231466.ref007]\]. Aucklandia lappa Decne has been used in China for the treatment of asthma, anorexia, nausea, ulcers and stomach problems for many years \[[@pone.0231466.ref008],[@pone.0231466.ref009]\]. It is also considered as an anti-cancer herb. Recent studies have shown that the ethanol extract of Aucklandia lappa Decne has anti-cancer effect on prostate cancer, oral cancer, breast cancer, and cervical cancer \[[@pone.0231466.ref010]--[@pone.0231466.ref012]\]. In addition to its anti-tumor chemo-preventive effect, Costunolide also has anti-cancer activity against various cancer cells such as lung cancer, breast cancer, and liver cancer, and can inhibit the invasion and metastasis of cancer cells \[[@pone.0231466.ref013]--[@pone.0231466.ref019]\]. Although Berberine and Costunolide have decent anti-cancer activity, it is not clear whether Berberine and Costunolide are key functional components of DHW, and the benefits of this combination for liver cancer treatment. In this study, we examined the effect of DHW on hepatoma cell proliferation and further explored its underlying mechanisms.

Epidermal growth factor (EGF) signaling is a core signaling pathway that regulates cell proliferation. Epidermal growth factor receptor (EGFR) amplification and its abnormal activity are tightly linked to the occurrence and development of various malignant tumors including liver cancer \[[@pone.0231466.ref020],[@pone.0231466.ref021]\]. Therefore, key molecules in EGFR signaling are considered to be important oncogenic factors and critical therapeutic targets. For example, Cetuximab, a chimeric (mouse/human) monoclonal antibody against EGFR, was approved by FDA in 2004 and by CHMP in 2008 in combination with platinum-based therapy for the treatment of patients with squamous cell carcinoma of the head and neck with metastatic disease, and in combination with radiation therapy for locally advanced cancer \[[@pone.0231466.ref022]\]. Gefitinib, a small molecular EGFR inhibitor, is approved for the treatment of patients with non-small cell lung cancer (NSCLC) after failure of both platinum-based or docetaxel chemotherapies \[[@pone.0231466.ref022],[@pone.0231466.ref023]\].

In addition to EGFR phosphorylation, homeostasis of EGFR is also critical for EGF signaling. This homeostasis is maintained by modulating endocytosis, degradation and recycling of the EGFR \[[@pone.0231466.ref024]--[@pone.0231466.ref026]\]. When EGFR is activated, endocytosis occurs through two pathways: clathrin-dependent and clathrin-independent. Typically, EGFR binds to a ligand and is engulfed by primary endocytosis, converting from a membrane distribution to an intracytoplasmic vesicle distribution. After signaling to downstream molecules, a portion of the EGFR can escape from primary endocytosis and be recycled to the membrane to continue binding to the ligand. For EGFR that cannot be separated from primary endocytosis, the ubiquitin-protease system will be activated to degrade EGFR when primary endocytic vesicles grow into secondary vesicles and bind to lysosomes \[[@pone.0231466.ref027],[@pone.0231466.ref028]\]. EGFR homeostasis is maintained by receptor internalization processes, including endocytosis, ubiquitination and degradation, leading to well-controlled activation of downstream signaling cascades. The ubiquitination of EGFR is a key regulatory node of this process and is then critical for the output of EGF signaling.

In the present study, we demonstrate that DHW inhibits the proliferation of hepatoma cells by modulating the EGF signaling pathway. In addition, the two active ingredients of DHW, Berberine and Costunolide have a dramatic synergistic effect on inhibiting the proliferation of liver cancer cells. This synergistic effect can be attributed in part to Berberine promoting endocytosis of activated EGFR, while Costunolide increases ubiquitination of EGFR and reduces EGFR recycling to cell membrane distribution.

Materials and methods {#sec002}
=====================

Chemicals and reagents {#sec003}
----------------------

Cell cycle and apoptosis analysis kit, EdUrd Cell Proliferation Kit with Alexa Fluor 488 and Anti-ubiquitin antibody were purchased from Beyotime (Nanjing, China); Anti-EGFR, Anti Phospho-EGFR and β-actin antibodies were from Abcam(Cambridge, UK); The herb plant materials of Coptidis Rhizoma and Aucklandia lappa Decne were purchased from TongRenTang pharmacy (BeiJing, China); Berberine and Costunolide with the purity of 98.8% used as the positive control was obtained from food and drug testing institute (Bei Jing, China).

Preparation of DHW extracts and determination of its active constituents {#sec004}
------------------------------------------------------------------------

According to the proportion of the prescriptions of DHW, weighed the same amount of each medicinal herbs and crushed them. 500 g of the mixed drug powder was taken, and 8 times of 75% ethanol was added there to, and the mixture was heated under reflux for 3 times for 1.5 hrs, filtered, and the filtrate was combined. Ethanol was recovered by evaporation on a rotary evaporator and dried in a vacuum rotary concentrator.

The sample was analyzed using a Shimadzu Prominence LC‑20A series HPLC apparatus (Shimadzu Co., Kyoto, Japan) equipped with auto sample injector (SIL‑20AC) and PDA photo diode array detector (SPD‑M20A). Berberine was separated by water and acetonitrile (50:50, v/v) at a flow rate of 1.0 ml/min. The column used for Berberine was the Hypersi1 ODS2 (100 mm × 4.6 mm, 5 μm particle size), and Berberine was detected at 345 nm. The mobile phase for Costunolide was comprised of acetonitrile/water (65:35, v/v). The solvent flow rate was 1.0 ml/min and Costunolide was detected at 225 nm. Contents of Berberine and Costunolide in DHW extracts were determined by referring to the calibration curve established by running standard at varying concentrations under the same conditions.

Cell lines and cell culture {#sec005}
---------------------------

Human hepatocellular carcinoma cell lines (PLC/PRF/5, SMMC-7721, Hur-7, HCC-LM3 and HepG2) and QSG-7701 hepatocyte cell line were obtained from the Shang Hai Cell Biology Institute of Chinese Academy of Science (Shanghai, China). The cells were cultured in a medium containing 10% FBS and RPMI 1640, and changed every 2 days.

Cell viability assay {#sec006}
--------------------

All kinds of cancer cells were seeded in 96-well cell culture plates at the concentration of 2×10^3^ \~5×10^3^ cells per well. After incubation overnight, the medium was removed and replaced with fresh medium with or without DHW extract. Cell density was measured on day 1, 2, and 3 by using the3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) following the manufacturer\'s instructions. The absorbance of converted dye is measured at the wavelength of 490 nm and the absorbance is directly proportional to cell viability. All experiments were repeated at least three times.

Analysis of cell cycle and apoptosis by flow cytometry {#sec007}
------------------------------------------------------

To determine the cell cycle, 2 × 10^6^ cells/well were seeded in 6-well cell culture plates and treated with DWH at a final concentration of 40 *μ*g/ml. After 48 hrs treatment, both floating and trypsinized adherent cells were collected and fixed with 70% ethanol. After fixation, the cells were washed with ice PBS and stained with propidium iodide (PI) for 30 mins under subdued light. Stained cells were analyzed using BD FACS Calibur and CellQuest software (BD LSRFortessa, USA). For cell apoptosis, PLC/PRF/5 cells were indicated, collected, and stained with Houchst33342 and PI as recommended by the manufacturer. Apoptotic cells were detected by flow cytometry, and the extent of apoptosis was calculated with FlowJo software (version 7.6.1).

EdUrd incorporation assay {#sec008}
-------------------------

To determine EDUrd incorporation, PLC/PRF/5 cells were seeded in sterile chamber-well slides. After 24 hrs of plating, incubation was continued for another 48 hrs in absence (control) or presence of different testing agents as described in the legends to the figures. At the end of the 48 hrs incubation period, added to the medium along with EDUrd (20 μM). After 2 hrs, the percentage of EDUrd positive cells were determined examined a fluorescence microscope.

Immunoprecipitation and Western blot analysis {#sec009}
---------------------------------------------

After drug treatment, PLC/PRF/5 cells were lysed with NP-40 buffer and the protein concentration of was determined by Bradford protein assay kit (thermo fisher). For Immunoprecipitation, equal amount (0.2 \~ 1 mg) of total protein samples were incubated with EGFR antibodies at 4°C overnight with gentle mixing, followed by the addition of 20 *μ*l of protein A/G beads and continued incubation for another 2 hrs. The beads were pelleted via centrifugation at 2500 rpm for 3 mins and washed five times with NP-40 buffer. The precipitated proteins were eluted in 40 *μ*l of lysate sample buffer. For Western blot analysis, the proteins were subjected to 4\~15% SDS-PAGE and transferred to nitrocellulose membranes (Amersham Biosciences, Buckinghamshire, UK). The membranes were blocked with 5% milk and were incubated with the indicated primary antibodies. Odyssey infrared fluorescence scanning imaging system can read the film and conduct semi-quantitative analysis.

Cell surface protein biotinylation and internalization assay {#sec010}
------------------------------------------------------------

Cell surface protein was isolated using Pierce Cell Surface Protein Isolation Kit (Pierce, Rockford, IL). Briefly, after drug treatment, PLC/PRF/5 cells were washed three and suspended in ice-cold PBS (pH 8.0). Biotinylation was performed by incubating cells in PBS containing EZ-link Sulfo--NHS--SS--biotin for 30 mins. Cells were subsequently washed three times with ice-cold PBS to remove unreacted reagent. Labelled cells were lysed and cell surface proteins were immunoprecipitated with avidin resin and analyzed by immunoblot with EGFR antibody.

EGFR internalization was performed using Pierce Cell Surface Protein Isolation Kit as well. Briefly, the proteins on the cells surface were first Biotinylated with reducible Sulfo-NHS-SS-biotin at 4 °C. The biotin reaction was quenched for 10 mins with 0.1 M lysine (Thermo Fisher). After they were washed with PBS, cells were added to pre-warmed culture medium (without or with the different treatment compounds) and incubated at 37°C for the indicated time. After stimulation with EGF 10ng/ml, cell surface biotin was removed by treatment (2 × 20 mins) at 4 °C with sodium 2-mercaptoethanesulphonate (MesNa). The internalized proteins were immunoprecipitated with avidin resin and analyzed by immunoblot with EGFR antibody.

Statistical analysis {#sec011}
--------------------

All statistical analyses were performed using Graph Pad Prism. The data shown represents the mean ± SD from at least three independent experiments. Student's t-test was used to compare two groups. ANOVA (One-way analysis of variance) used to analyze statistical differences between groups under different conditions. P values \< 0.05 is considered to have significance.

Result {#sec012}
======

DHW extract inhibits the proliferation of hepatoma cells {#sec013}
--------------------------------------------------------

DHW is a traditional herbal medicine used in Mongolia for the treatment of liver cancer for many years. The drug is claimed to have a clinically inhibitory effect on tumor progression. But so far, there are no well-controlled scientific experiments to verify the validity of DHW prescription. In this study, we first prepared DHW extract by refluxing DHW in ethanol. Then, we examined the effects of DHW extract on the growth of various liver cancer cells. PLC/PRF/5 hepatoma cells or QSG-7701 human hepatocytes were seeded in 12-well plates for 24 hrs and then these cells were treated with DHW extract. The number of cells was counted after 2, 4, and 6 days. We found that DHW extract significantly inhibited the growth of PLC/PRF/5 cell, while it had limited effect on the growth of QSG-7701 cells ([Fig 1A and 1B](#pone.0231466.g001){ref-type="fig"}). We then further quantified the inhibitory effect of DHW extract on various liver cancer cells. SMMC-7721, Hur7, HepG2, and LM3 cells were seeded in 96-well plates for 24 hrs and then treated with different dose of DHW extract (20 \~ 500 *μ*g/ml). Cell viability was measured after 24, 48 and 72 hrs. The IC~50~ values of these liver cancer cells was calculated ([Table 1](#pone.0231466.t001){ref-type="table"}). As shown in [Fig 1C](#pone.0231466.g001){ref-type="fig"}, DHW extract inhibited the growth of SMMC-7721, HepG2, Hur7, and LM3 cells in a dose-and time-dependent manner, and these cells have different sensitivities against DHW extract. The effect of DHW on the QSG-7701 human hepatocytes was limited ([Fig 1B](#pone.0231466.g001){ref-type="fig"}), indicating that the inhibition of DHW on the growth of various liver cancer cell lines should not be derived from cytotoxicity.

![PLC/PRF/5 (A), and QSG-7701 (B), cells (2×10^4^) were seeded in 12-well plates and cultured in DMEM treated with DHW (40 *μ*g/ml). The number of cells was counted at the indicated times. C, Cell viability determined by MTT assay. Liver cancer cells were treated with different concentrations of DHW extract for 24, 48, and 72 hrs, and cell viability was determined by MTT. D, DHW extract induces G0/G1 arrest of PLC/PRF/5 cell line. Cells were treated without or with 40 *μ*g/ml DHW extract for 48 hrs and then the cell cycle population was measured by flow cytometry. E, Apoptosis in PLC/PRF/5 cells determined by flow cytometry. Cells were treated without or with 40 *μ*g/ml DHW extract for 48 hrs, and then apoptosis was measured by flow cytometric analysis of cells stained with Houchest3324 and PI. The percentages of Houchest3324 or/and PI-positive cells are indicated. F, PLC/PRF/5 Cells were treated with DHW extract for 48 hrs before they were assayed for EdUrd incorporation. Data are presented as the mean ±SD of values from triplicate experiments.](pone.0231466.g001){#pone.0231466.g001}

10.1371/journal.pone.0231466.t001

###### IC~50~ values of DHW extract on different cell lines.

![](pone.0231466.t001){#pone.0231466.t001g}

  Cell line   IC~50~ values (μg/ml)                 
  ----------- ----------------------- ------------- -------------
  PLC/PRF/5   213.10±1.07             68.95±1.42    43.29±1.34
  HepG2       376.30±0.78             178.90±0.98   119.90±0.84
  LM3         438.60±0.89             150.90±1.06   128.80±1.11
  Hur7        338.50±1.06.            212.80±1.05   171.50±0.95
  SMMC7721    341.20±1.00             220.70±1.25   147.14±1.17

To determine whether DHW inhibits the growth of hepatoma cells by blocking the cell cycle or inducing apoptosis, we examined the cell cycle distribution and apoptosis of PLC/PRF/5 cells after DHW treatment. Among the cell lines we examined, PLC/PRF/5 cell is the most sensitive to DHW treatment (IC~50~ value: 43.29 ± 1.34 *μ*g/ml for 72 hrs treatment, [Table 1](#pone.0231466.t001){ref-type="table"}). PLC/PRF/5 cells were cultured for 24 hrs, then treated with 40 *μ*g/ml DHW extract for 48 hrs, and analyzed by flow cytometry. We found that the number of cells arrested in the G0/G1 phase increased by 20%, while the proportion of cells in the S phase decreased sharply by 16% ([Fig 1D](#pone.0231466.g001){ref-type="fig"}). As shown in [Fig 1E](#pone.0231466.g001){ref-type="fig"}, the apoptosis of PLC/PRF/5 cells increased only slightly from 2.5 ± 0.4% to 3.8 ± 0.7% after 48 hrs of treatment with 40 *μ*g/ml DHW extract. This result indicates that DHW does not inhibit PLC/PRF/5 cells by inducing apoptosis. With EDUrd incorporation assay, we further confirmed that DHW extract significantly inhibited DNA synthesis in PLC/PRF/5 cells ([Fig 1F](#pone.0231466.g001){ref-type="fig"}). The result in [Fig 1](#pone.0231466.g001){ref-type="fig"} demonstrates that DHW extract inhibits the proliferation of hepatoma cells.

Berberine and Costunolide, two key active components in DHW, synergistically inhibit hepatoma cell proliferation {#sec014}
----------------------------------------------------------------------------------------------------------------

DHW is a traditional herbal medicine consisting of Coptidis Rhizoma and Aucklandia lappa Decne, with a ratio of 1:1 (w/w). It is well known that Berberine and Costunolide are the main bioactive components of Coptidis Rhizoma and Aucklandia lappa Decne \[[@pone.0231466.ref029]\]. Therefore, we first quantified the content of Berberine (5.6%) and Costunolide (1.2%) in DHW extract by HPLC ([Fig 2A and 2B](#pone.0231466.g002){ref-type="fig"}). Then, pure Berberine (2.5 *μ*g/ml) and Costunolide (0.5 *μ*g/ml) were mixed according the abundance determined above to form a Berberine-Costunolide mixture (named as BC mix here after). PLC/PRF/5 cells were incubated with Berberine (2.5 *μ*g/ml), Costunolide (0.5 *μ*g/ml), this BC mix, or 40 *μ*g/ml DHW extract for 48 hrs. EDUrd incorporation assay was then performed. As shown in [Fig 2C](#pone.0231466.g002){ref-type="fig"}, both Berberine and Costunolide inhibited the proliferation of PLC/PRF/5 cells. The BC mix and DHW extract had similar inhibitory effects on PLC/PRF/5 cells ([Fig 2C](#pone.0231466.g002){ref-type="fig"}). The inhibitory effect of BC mixture or DHW extract on PLC/ PRF/5 cells was better than that of Berberine or Costunolide alone ([Fig 2C](#pone.0231466.g002){ref-type="fig"}). The results indicate that Berberine and Costunolide are indeed anti-cancer active ingredients of DHW, and the combination of Berberine and Costunolide is sufficient to mimic the inhibition of DHW on PLC/PRF/5 cells.

In these experiments ([Fig 2C](#pone.0231466.g002){ref-type="fig"}), we noted that the inhibitory effect of BC mix on PLC/PRF/5 cell proliferation was greater than the sum of the inhibitory effects of Berberine and Costunolide. To evaluate the combined effects of Berberine and Costunolide on PLC/PRF/5 cells, we treated PLC/PRF/5 cells with different concentrations of BC mix. As shown in [Fig 2D](#pone.0231466.g002){ref-type="fig"}, the treatment with BC mix was more effective in inhibiting the proliferation of PLC/PRF/5 cells than the sum of the inhibitory effects of using Berberine or Costunolide alone. The results showed that the combination of Berberine and Costunolide has a synergistic effect on inhibiting the proliferation of hepatoma cells. Subsequently, we used the Calcusyn software program for median analysis. The median effect analysis was then performed using the Calcusyn software program. The effect of constant ratio of Berberine and Costunolide on the growth of the PLC/PRF/5 cells was calculated. The data obtained in this study were analyzed by the Chou-Talalay method, and the synergistic effects were analyzed by the combination index (CI). CI \<1, = 1, and \>1 represent synergistic, additive, and antagonistic effects, respectively \[[@pone.0231466.ref030]\]. We found that four of the five BC mix concentrations used in this experiment had a combined index of less than 1 (CI\<1) ([Fig 2E](#pone.0231466.g002){ref-type="fig"}), indicating that the Berberine and Costunolide have synergistic anti-tumor effects ([Table 2](#pone.0231466.t002){ref-type="table"}). This synergistic effect brings the extra benefit of a combination of Coptidis Rhizoma and Aucklandia lappa Decne, which supports the value of DHW formula.

![A, Panel 1 is the chromatogram and structure of Berberine standard; Panel 2 is the chromatogram of DHW samples; High performance liquid chromatograms. B, Panel 1 is the structure and chromatogram of Costunolide standard, Panel 2 is the chromatogram of DHW samples in different analysis. Arrows indicate the peaks representing Berberine or Costunolide; C, EdUrd incorporation assays were performed on PLC/PRF/5 cells treated with either DMSO (control), Berberine (2.5 *μ*g/ml) and/or Costunolide (0.5 *μ*g/ml), DHW extract (40 *μ*g/ml). The percentage of cells incorporating EDUrd after 48 hrs was shown. D, PLC/PRF/5 cells were treated with Berberine (Ber) and Costunolide(Cos) or both (BC mix) in a fixed ratio (5:1) for 48 hrs. Cell viability was measured by MTT assay. E, CI was calculated by isobologram analysis using the Chou-Talalay method. CI = 1, additive effect; CI \<1, synergistic effect; CI, \>1, antagonistic effect. Data represented are from three independent experiments.](pone.0231466.g002){#pone.0231466.g002}

10.1371/journal.pone.0231466.t002

###### Synergistic effects of Berberine with Costunolide on growth of PLC/PRF/ 5 cells.

![](pone.0231466.t002){#pone.0231466.t002g}

  Dose (*μ*g/mL)   Fraction of Cells Affected (FA)   CI              
  ---------------- --------------------------------- ------- ------- -------
  2.5              0.168                             0.153   0.276   1.095
  5.0              0.394                             0.436   0.509   0.935
  10               0.405                             0.449   0.681   0.895
  15               0.688                             0.520   0.834   0.578
  20               0.778                             0.531   0.880   0.533

Abbreviations are as follows: FA, Fraction of cells with growth affectedin response to Berberine and /or Costunolide treated vs. uncreated cells; CI, combination Index. CI \< 1.0 indicates synergism.

DHW inhibits the proliferation of hepatoma cells by regulating EGF signaling pathway {#sec015}
------------------------------------------------------------------------------------

We set out to explore the potential mechanism by which DHW inhibits the proliferation of liver cancer cells. EGF signaling is a core signaling pathway that regulates cell proliferation. Overexpression of EGFR and its abnormal activity are closely related to the occurrence and development of various malignant tumors including liver cancer. Therefore, we first determined the expression and activation of EGFR in hepatoma cells such as PLC/PRF/5, HCC-LM3, HepG2, Hur7, SMMC-7721 cells. QSG-7701 human hepatocyte was used as controls. As shown in [Fig 3A](#pone.0231466.g003){ref-type="fig"}, both EGFR expression and phosphorylation were significantly increased in hepatoma cells compared to normal hepatocytes ([Fig 3A](#pone.0231466.g003){ref-type="fig"}, 1^st^ panel from top, lanes 1--5, compared to lane 6). We further confirmed that EGF signaling is critical for the proliferation of liver cancer cells by EGFR inhibitor SC0186. PLC/PRF/5, LM3, HepG2, Hur7, SMMC-7721 cells were cultured and then treated with 10mM SC0186 for 24 hrs. The proliferation of these cells was inhibited by SC0186, and EGFR phosphorylation of these cells was also blocked ([Fig 3B](#pone.0231466.g003){ref-type="fig"}, 1^st^ panel from top, lane 1--5).

![A, the expression and activation of EGFR in hepatoma cells such as PLC/PRF/5, HCC-LM3, HepG2, Hur7 and SMMC-7721 cells compared to normal hepatocytes; B, The EGFR and P-EGFR levels in HCC cells were examined by Western blot after treatment treated with 10mM SC0186 for 24 hrs; C, PLC/PRF/5 cells were treated with DHW extract, Berberine, Costunolide or BC mix at concentrations of 40 μg/ml, 2.5 *μ*g/ml and 0.5 *μ*g/ml for 48 hrs, and then the expression levels of the relevant factors (EGFR, P-EGFR, Akt, P-Akt, ERK, P-ERK) were determined by Western blot; D, Effect of DHW extract, he EGFR inhibitor SC0186 and the combination of DHW extract and SC0186 on cellular growth and morphological changes of PLC/PRF/5 cells.](pone.0231466.g003){#pone.0231466.g003}

Since EGF signaling is critical for the proliferation of hepatoma cells, we then further explored whether DHW inhibits hepatoma cell proliferation by regulating EGF signaling. PLC/PRF/5 cells were cultured and incubated with DHW extract, Berberine, Costunolide, or BC mix for 48 hrs. As shown in [Fig 3](#pone.0231466.g003){ref-type="fig"}, the expression and phosphorylation of EGFR were significantly reduced after treatment with DHW extract or BC mix ([Fig 3C](#pone.0231466.g003){ref-type="fig"}, 1^st^ Panel from top, lane 1 and 5 compared to lane 2; 2^nd^ Panel from top, lane 1 and 5 compared to lane 2). Examination on the activities of the downstream kinases of EGF signaling revealed that the Protein Kinase B (AKT) phosphorylation was remarkably inhibited, whereas Extracellular signal-regulated kinase (ERK) phosphorylation was up-regulated ([Fig 3C](#pone.0231466.g003){ref-type="fig"}, 1^st^ panel from top, lane 6 and 10 compared to lane 7; [Fig 3C](#pone.0231466.g003){ref-type="fig"}, 1^st^ panel from top, lane 11 and 15 compared to lane 12). We further confirmed this result with the EGFR inhibitor SC0186. Both DHW extract and the EGFR inhibitor SC0186 significantly inhibited the growth of hepatoma cells ([Fig 3D](#pone.0231466.g003){ref-type="fig"}). However, DHW extract alone and the combination of DHW extract and SC0186 have the similar inhibition on PLC/PRF/5 cell proliferation ([Fig 3D](#pone.0231466.g003){ref-type="fig"}). We believe that this is because DHW inhibits cell proliferation primarily through EGF signaling, and the use of the EGFR inhibitor SC0186 in combination with DHW does not provide additional benefits. Therefore, this result indicates that DHW inhibits hepatoma cell proliferation by modulating EGF signaling.

Berberine and Costunolide promote the endocytosis and degradation of EGFR respectively {#sec016}
--------------------------------------------------------------------------------------

EGF signaling is the core of cell proliferation and is always tightly controlled. Upon activated by extracellular signals, phosphorylated EGFR is endocytosed through either clathrin-dependent or clathrin-independent pathways \[[@pone.0231466.ref026]\]. When EGFR is endocytosed, it is then ubiquitinated and directed to lysosomes for degradation. There are also some EGFR that will be recycled back to the cell surface to participate in the new activation process. Endocytosis and degradation of EGFR shut down the activated EGF signaling, allowing for tight regulation of the EGF signaling pathway. In addition to, for example, mutation-induced hyperphosphorylation of EGFR, the abnormalities in EGFR signaling are more due to the disruption of the balance of EGFR endocytosis and degradation.

In this study, we found that DHW inhibits hepatoma cell proliferation by blocking EGF signaling ([Fig 3C](#pone.0231466.g003){ref-type="fig"}). Therefore, we first examined whether Berberine and Costunolide inhibit EGF signaling by directly blocking EGFR phosphorylation. PLC/PFR/5 cells were serum-starved and incubated with Berberine, Costunolide, BC mix, or DHW extract for 24 hrs, and then stimulated by EGF (10 ng/ml) for 30 mins. As shown in [Fig 3C](#pone.0231466.g003){ref-type="fig"}, although both Berberine and Costunolide reduced EGFR phosphorylation in PLC/PFR/5 cells cultured in full serum ([Fig 3C](#pone.0231466.g003){ref-type="fig"}, 1^st^ panel from top, lane 3 and 4 compared to lane 2), but neither Berberine nor Costunolide blocked EGFR phosphorylation stimulated by EGF ([Fig 4A](#pone.0231466.g004){ref-type="fig"}, 1^st^ panel from top, lane 8 and 9 compared to lane 7). DHW extract or BC mix also failed to prevent EGF-stimulated EGFR phosphorylation ([Fig 4A](#pone.0231466.g004){ref-type="fig"}, 1^st^ panel from top, lane 6 and 10 compared to lane 7), while both inhibited EGFR phosphorylation in cells cultured in full serum ([Fig 3C](#pone.0231466.g003){ref-type="fig"}, 1^st^ panel from top, lane 1and 5 compared to lane 2). We also noticed that DHW extract treatment significantly reduced EGFR expression in cells cultured in full serum ([Fig 3C](#pone.0231466.g003){ref-type="fig"}, 2^nd^ Panel from top, lane1 compared to lane 2). All of these results indicate that DHW or its major active ingredient, Berberine or Costunolide, does not directly target EGFR phosphorylation, but indirectly reduces EGF signaling over a longer period of time. Therefore, we suspect that Berberine or Costunolide might target the endocytosis and degradation processes of EGFR.

![A, PLC/PFR/5 cells were serum-starved and incubated without (control) or with Berberine, Costunolide and BC mix for 24 hrs, and then stimulated by EGF (10ng/ml) for 30 mins. The expression level of P-EGFR in PLC/PRF/5 cells was examined by Western blot. B, EGFR on the surface of PLC/PRF/5 cells were examined by immunofluorescence after treated with Berberine, Costunolide and BC mix for 24 hrs, and then stimulated by EGF (10ng/ml) for 30 mins; C, PLC/PFR/5 cells were serum-starved and incubated without (control) or with Berberine, Costunolide, and BC mix for 24 hrs, and then stimulated by EGF (10ng/ml) for 30 mins. Proteins on cell surface were labeled with Sulfo-NHS-SS-Biotin and isolated by streptavidin and then analyzed by immunoblot detected EGFR (lane5-8); The internalized cell surface proteins were isolated using Sulfo-NHS-SS-Biotin and MesNa and analyzed by immunoblot detecting EGFR (top panel) (lane9-12). D, PLC/PRF/5 cells were incubated without (control) or with Berberine, Costunolide, and BC mix for the indicated time periods. Ubiquitinated EGFR was examined via EGFR immunoprecipitation followed by immunoblotting with an ubiquitin antibody. The bands were quantified. The level of ubiquitinated EGFR was normalized to the immunoprecipitated EGFR. The relative density of the control.](pone.0231466.g004){#pone.0231466.g004}

We set out to examine the effects of Berberine or Costunolide on the endocytosis and ubiquitination of EGFR. We used immunofluorescence to detect the presence of EGFR on the surface of PLC/PRF/5 cells. As shown in [Fig 4B](#pone.0231466.g004){ref-type="fig"}, Berberine, Costunolide, or BC mix attenuated the presence of EGFR on the surface of PLC/PRF/5 cells ([Fig 4B](#pone.0231466.g004){ref-type="fig"}, picture from left, picture 2--4 compared to picture 1). We then isolated cell surface EGFR using EZ-link Sulfo--NHS--SS--biotin. Costunolide and BC mix significantly reduced the amount of EGFR on the cell surface ([Fig 4C](#pone.0231466.g004){ref-type="fig"}, 1^st^ panel from top, lane6 and 8 compared to lane 5). The reduced cell surface EGFR may be due to a decrease of EGFR precursor transport resulting in reduced amount of cytoplasmic protein to the cell surface, or the accelerated endocytosis of EGFR from the cell surface. Therefore, we examined the effect of Berberine or Costunolide on the EGFR internalization after EGF stimulation. We first labeled the cell surface proteins with Sulfo--NHS--SS--biotin and then incubated these PLC/PRF/5 cells with Berberine, Costunolide, or BC mix as indicated. The biotin label of the cell surface proteins were then stripped with MesNa. Therefore, the signals we detected represent internalized cell surface proteins. As shown in [Fig 4](#pone.0231466.g004){ref-type="fig"}, after Berberine treatment, the internalization of cell surface EGFR was enhanced, while Costunolide had no significant effect on the internalization of EGFR ([Fig 4C](#pone.0231466.g004){ref-type="fig"}, 1^st^ panel from top, lane10 and lane11 compared to lane 9). This result indicates that Berberine promotes the internalization of EGFR. Subsequently, we evaluated EGFR ubiquitination in PLC/PRF/5 cells exposed to Berberine, Costunolide, BC mix via immunoprecipitation with anti-EGFR antibody followed by immunoblotting with an anti-ubiquitin antibody. We found that Costunolide and BC increased EGFR ubiquitination, while Berberine has a limited effect on EGFR ubiquitination ([Fig 4D](#pone.0231466.g004){ref-type="fig"}, 1^st^ panel from top, lane 2, 3 and 4 compared to lane 1). These results demonstrated that Berberine and Costunolide target different processes of EGFR degradation. Berberine promotes the internalization of EGFR while Costunolide can increase EGFR ubiquitination. This also explains why the combination of Berberine and Costunolide has a synergistic effect on EGF signaling, thereby providing DHW with an additional advantage of inhibiting cancer cell proliferation and treating cancer.

Discussion {#sec017}
==========

DHW is a traditional herbal medicine used by Mongolians for many years. Although the underlying mechanisms are unclear, the drug does benefit cancer patients. For many traditional herbal medicines, the situation is similar: there are no well-controlled scientific experiments to verify the validity of these drugs, and there are no clues about their underlying mechanisms and side effects, which greatly limits clinical applications and further optimization of these drugs. In this study, we first demonstrated that DHW inhibits the proliferation of hepatoma cells by modulating EGF signaling. Berberine and Costunolide are the main active ingredients in DHW. Berberine promotes endocytosis of activated EGFR, while Costunolide increases ubiquitination of EGFR and reduces the distribution of EGFR on the cell membrane, thereby inhibiting the activation of EGF signaling. Berberine and Costunolide target different processes of EGFR degradation, resulting in a significant synergistic effect in inhibiting cell proliferation. This is the benefit of a combination of Berberine and Costunolide in the DHW formula. In addition, neither Berberine nor Costunolide directly target EGFR phosphorylation. This allows DHW to be used as a supplementary medicine to tyrosine kinase inhibitors in cancer therapy.

EGF signaling is a key signaling pathway that regulates cell proliferation. Extracellular signal molecules stimulate EGFR phosphorylation and then trigger this signal cascade. Phosphorylation of EGFR also initiates the internalization of EGFR, thereby shutting down the EGF signaling. Phosphorylated EGFR will then be ubiquitinated and engulfed by primary endocytosis, transforming from a membrane distribution to an intracytoplasmic vesicle distribution. Primary endocytic vesicles grow into secondary vesicles and bind to lysosomes, and the ubiquitin-protease system can be activated to degrade EGFR \[[@pone.0231466.ref024],[@pone.0231466.ref031]\]. We found that both Berberine and Costunolide target and facilitate the EGFR internalization and degradation system. The synergistic effect of the combination of Berberine and Costunolide suggests that they target different EGFR internalization and degradation processes. We further demonstrate that Berberine promotes endocytosis of activated EGFR, while Costunolide increases ubiquitination of EGFR. However, the exactly targets of Berberine and Costunolide remain unclear. To identify these targets and underlying mechanisms, further experiments are necessary in the future.

In this study, we focused on the effects of Berberine and Costunolide on EGF signaling. As natural compounds, Berberine and Costunolide may target other signaling cascades. Previous studies have shown that Berberine prevents secretion of VEGF from HCC and down-regulating VEGF mRNA expression \[[@pone.0231466.ref032]\]. Costunolide also inhibits proliferation and survival of colorectal cancer cells via inhibiting Wnt/β-Catenin signaling pathway \[[@pone.0231466.ref033]\]. Although we cannot rule out the possibility of Berberine and Costunolide targeting other signaling pathways, we did demonstrate in this study that in certain tumor cells, like PLC/PRF/5, HT29, and HCC-LM3, Berberine and Costunolide inhibit tumor cell proliferation by modulating EGF signaling.

DHW is a traditional herbal medicine. In this study, we determined that Berberine and Costunolide are the main active components in DHW. This does not exclude the presence of other active ingredients in the DHW. In fact, Coptidis Rhizoma is composed of various alkaloids, including Berberine, coptisine, palmatine, and jatrorrhizine. Aucklandia lappa Decne root extract contains resinoids, essential oil, alkaloid, inulin, a fixed oil, and other minor ingredients such as tannins and sugars \[[@pone.0231466.ref012]\]. In this study, we found that BC mix and DHW extract have similar inhibitory effects on PLC/PRF/5 cell proliferation ([Fig 2C](#pone.0231466.g002){ref-type="fig"}). They inhibited PLC/PRF/5 cells better than either Berberine or Costunolide alone ([Fig 2D](#pone.0231466.g002){ref-type="fig"}). Therefore, at least for certain liver cancer cell such as PLC/PRF/5 cells, Berberine and Costunolide are indeed the main anti-cancer active ingredients of DHW.

As summarized in [Fig 5](#pone.0231466.g005){ref-type="fig"}, our study indicates that Berberine and Costunolide are key active ingredients for inhibiting the growth of hepatoma cell by DHW extract *in vitro*. Berberine and Costunolide target different steps of EGFR internalization and degradation, and mutually enhance the inhibition on EGF signaling, resulting in a synergistic anti-cancer effect ([Fig 5](#pone.0231466.g005){ref-type="fig"}). These results suggest that the combination of Berberine and Costunolide is a potential anti-tumor drug for the treatment of liver cancer, and also provides a new understanding of the mechanism of action of traditional Mongolian medicines.

![A model for the function of DHW in EGFR homeostasis.\
Berberine and Costunolide are the main active ingredients in DHW. Berberine promotes endocytosis of activated EGFR, while as Costunolide increases ubiquitination of EGFR and reduces EGFR recycling to cell membrane distribution, thereby inhibiting EGF signaling. Part of internalized EGFR goes into early endosomes (A). Following their internalization into early endosomes, nonubiquitinated receptors are recycled back to the plasma membrane (C). Part of internalized EGFR is ubiquitinated (B). Ubiquitinated EGFRs proceed toward the multivesicular bodies (D). Ubiquitinated cargo pour into lysosomes for degradation (E).](pone.0231466.g005){#pone.0231466.g005}
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Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript named "DaHuangWan targets EGF signaling to inhibit the proliferation of hepatoma cells" identifies the main active ingredients in DaHuangWan (DHW) and reveals the underlying mechanisms of treating liver cancer. It also provides basis for reveals the mechanisms of herb pair. Overall the manuscript is a generally well presented paper with a good design. However, I think there are still some areas that need to be improved to achieve the quality of publication in this journal. I would recommend the paper for publication with minor revisions as addressed in the comments section bellow.

Question 1: How to determine the concentration of DHW extract is 40 μg/mL and the treat time is 48 h? When the patient is treated with DHW normally, can the effective physiological concentration in the body reach 40 μg/mL?

Question 2: Page 6, Line 116, whether the concentration range of DHW extract (40\~500 μg/mL) is non-toxic to QSG-7701 human hepatocytes?

Question 3: Page 6, Line 117-118, "The IC50 values of these liver cancer cells was 118 calculated.", please add the Table1 for better illustration.

Question 4: Figure 2C, there are two DHW, please confirm.

Question 5: Figure 2D, the abscissa position is offset, please correct.

Question 6: Figure 4B, why is there no "merge" picture for better illustration?

Question 7: Table 2, "Dose" is berberine dose, but the title is "Synergistic effects of Berberine with Costunolide on growth of PLC/PRF/ 5 cells", please make it clear.

Question 8: Page 7, Line 143, which is the final concentrations of berberine and costunolide respectively in the BC mix?

Question 9: Page 8, Line 165, where is the Fig.2E, please confirm.

Question 10: Please check all unit writing forms, such as "40 μg/mL" not "40μg/mL", "10 ng/ml" not "10ng/ml", "30 mins" not "30mins" and so on.

Question 11: Please unify the time form, "hrs", "hours", "h".

Question 12: Please confirm whether the berberine and costunolide initials need to be capitalized, the text is inconsistent.

Question 13: Page 16, Line 349, please change "of 40 g/ml After" to "of 40 g/ml. After".

Question 14: Page 19, Line 418, "DMEM supplemented with DHW (40μg/ml)." , please unify the font form.

Question 15: Page 20, Line 458, please change "(control)or" to "(control) or".

Question 16: Please check some latest published articles and modify the format of the references according the guidelines. Such as "Page 21, Line 470, Please add the issue number."

Question 17: Page 21, Line 492, Please check the page number.

Question 18: Page 22, Line 523, Please add the page number.

Question 19: Page 22, Line 536, Please check the page number.

Question 20: I recommend that the author add a model diagram of the mechanism for readers to better understand.

Reviewer \#2: The study investigates a Mongolian herbal medicine DaHuangWan in inhibiting hepatoma cell growth through inhibiting EGF signalling. However the following questions should be addressed before acceptance.

1\. There are so many signalling pathways related to cancer cell proliferation. Why did the authors target on EGFR signalling?

2\. Did the authors consider studying the anti-proliferative effect of other components in DHW? And how the authors exclude the possibility of combined toxicity of costunolide and berberine in the B+C mixture rather than synergistic effect?

3\. To confirm the DHW-regulated EGF signalling, it is more reasonable to rescue the EGFR expression rather than blocking it by inhibitor.

4\. It is interesting to show that berberine promotes endocytosis while costunolide promotes EGFR ubiquitination. But how did the authors explain for Fig 4D that berberine seems increase the ubiquitin level of EGFR.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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8 Mar 2020

Reviewer \#1: The manuscript named "DaHuangWan targets EGF signaling to inhibit the proliferation of hepatoma cells" identifies the main active ingredients in DaHuangWan (DHW) and reveals the underlying mechanisms of treating liver cancer. It also provides basis for reveals the mechanisms of herb pair. Overall the manuscript is a generally well presented paper with a good design. However, I think there are still some areas that need to be improved to achieve the quality of publication in this journal. I would recommend the paper for publication with minor revisions as addressed in the comments section bellow.

Question 1: How to determine the concentration of DHW extract is 40 μg/mL and the treat time is 48 h? When the patient is treated with DHW normally, can the effective physiological concentration in the body reach 40 μg/mL?

In this study, we first examined the effects of DHW extract (10 \~ 500 ug/ml) on the growth of various liver cancer cells. We found that 40 μg/ml DHW extract significantly inhibited the growth of PLC/PRF/5 cells while being non-toxic to QSG-7701 human hepatocytes (Figures 1A and 1B). Therefore, we consider 40 μg/ml DHW extract to be appropriate because it clearly demonstrates its effect on the proliferation of liver cancer cells and excludes the possibility of DHW extract toxicity. In addition, 40μg/ml DHW extract has around 2.5 ug/ml (\~ 8 uM) Berberine and 0.5 ug/ml Costunolide. 10 -- 30 uM berberine is commonly used for cell signal transduction studies through cell culture (e.g. Wang J et al. Oncotarget. November 15, 2016; 7 (46): 76076-76086).

The effective physiological concentration of DHW in the body has not been determined. However, physiological concentrations of Berberine have been reported. The 40 μg/ml DHW extract has about 2.5 ug/ml (\~8 uM) Berberine and 0.5 ug/ml Costunolide. Chen J et al. reported that after oral administration of Coptidis Rhizoma extract (0.15 g / 100 g body weight, containing 3.1% small base), Berberine is absorbed at a higher absorption rate, with a Tmax value of 58.21 ± 9.9 minutes and a Cmax value of 2.9 ± 1.1 μg/ml (Chen J et al. Bull. Korean Chem. Soc. 2013,5(34):1559-1562). Therefore, we believe that the effective physiological concentration of DHW extract in the body might reach 40 μg/ml.

Question 2: Page 6, Line 116, whether the concentration range of DHW extract (40\~500 μg/mL) is non-toxic to QSG-7701 human hepatocytes?

Yes, we examined the effects of DHW extract (concentration range of 10 \~ 500 ug/ml) on the growth of various liver cancer cells and QSG-7701 human hepatocytes. DHW extract inhibited the growth of SMMC-7721, HepG2, Hur7, and LM3 cells in a dose-and time-dependent manner, and these cells had different sensitivities against DHW extract (Figure 1C). Moreover, DHW extract (10\~500μg/mL) is non-toxic to QSG-7701 human hepatocytes.

Question 3: Page 6, Line 117-118, "The IC50 values of these liver cancer cells was 118 calculated.", please add the Table1 for better illustration.

We have added the Table 1 as requested by the reviewer. Please see Page 8, Line 232.

Question 4: Figure 2C, there are two DHW, please confirm.

We have fixed it as requested by the reviewer. Please see Figure 2C.

Question 5: Figure 2D, the abscissa position is offset, please correct.

We have fixed it as requested by the reviewer. Please see Figure 2D.

Question 6: Figure 4B, why is there no "merge" picture for better illustration?

The merged pictures have been added as requested by the reviewer.

Question 7: Table 2, "Dose" is berberine dose, but the title is "Synergistic effects of Berberine with Costunolide on growth of PLC/PRF/ 5 cells", please make it clear.

Synergies were analyzed by CalcuSyn software. It is pointed out in the CalcuSyn software usage guide: Enter the two (or more) drugs that form the combination/mixture using the approach for entering single drugs (e.g. Adhip P. N. et al. Nutrition and Cancer, 61(4), 544--553)

Question 8: Page 7, Line 143, which is the final concentrations of berberine and costunolide respectively in the BC mix?

The final concentrations of Berberine and Costunolide in BC mix are 2.5 𝜇g/ml and 0.5 𝜇g/ml respectively (Line 240-242).

Question 9: Page 8, Line 165, where is the Fig.2E, please confirm.

We have confirmed it (Line 263 now) as requested.

Question 10: Please check all unit writing forms, such as "40 μg/mL" not "40μg/mL", "10 ng/ml" not "10ng/ml", "30 mins" not "30mins" and so on.

We have checked and revised all unit writing forms as requested.

Question 11: Please unify the time form, "hrs", "hours", "h".

The time form has been unified to "hrs".

Question 12: Please confirm whether the berberine and costunolide initials need to be capitalized, the text is inconsistent.

The berberine and costunolide initials have been unified as capitalized.

Question 13: Page 16, Line 349, please change "of 40 g/ml After" to "of 40 g/ml. After".

We have fix it. Please see Page 6, Line 151.

Question 14: Page 19, Line 418, "DMEM supplemented with DHW (40μg/ml)." , please unify the font form.

We have revised it as requested by the reviewer. Please see Page 15, Line 426.

Question 15: Page 20, Line 458, please change "(control)or" to "(control) or".

We have revised it as requested. Please see Page 16, Line 458.

Question 16: Please check some latest published articles and modify the format of the references according the guidelines. Such as "Page 21, Line 470, Please add the issue number."

We have added the issue number. Please see Page 17, Line 489.

Question 17: Page 21, Line 492, Please check the page number.

We have fixed the page number. Please see Page 18, Line 512.

Question 18: Page 22, Line 523, Please add the page number.

We have added the page number as requested. Please see Page 19, Line 543.

Question 19: Page 22, Line 536, Please check the page number.

We have fixed the page number. Please see Page 19, Line 556.

Question 20: I recommend that the author add a model diagram of the mechanism for readers to better understand.

The model diagram of the mechanism has been added to the article as requested. Please see line 407-410 and Figure 5.

Reviewer \#2: The study investigates a Mongolian herbal medicine DaHuangWan in inhibiting hepatoma cell growth through inhibiting EGF signalling. However the following questions should be addressed before acceptance.

1\. There are so many signalling pathways related to cancer cell proliferation. Why did the authors target on EGFR signalling?

We did not specifically target EGF signaling. EGF signaling is a key signaling pathway that regulates cell proliferation. When we found that DHW inhibits hepatoma cell growth, we examined multiple signaling pathways including EGF signaling. Both EGFR expression and phosphorylation were significantly increased in hepatoma cells compared to normal hepatocytes (Figure 3A). The proliferation of these HCC cells was inhibited by EGFR inhibitors, and EGFR phosphorylation of these cells was also blocked (Figure 3B). These results confirm the central role of EGF signaling in the proliferation of liver cancer cells, and also lead us to target EGF signaling. As we have discussed in this manuscript: we cannot rule out the possibility that DHW targets other signaling pathways. Previous studies have shown that Berberine prevents HCC from secreting VEGF and down-regulating VEGF mRNA expression (ref. 32). Costunolide also inhibits the proliferation and survival of colorectal cancer cells via inhibiting Wnt/β-Catenin signaling pathway (ref. 33). Although we cannot rule out the possibility of Berberine and Costunolide targeting other signaling pathways, we did prove in this study that in certain tumor cells, like PLC/PRF/5, HT29, and HCC-LM3, DHW inhibit tumor cell proliferation by regulating EGF signaling (lines 389-396)

2\. Did the authors consider studying the anti-proliferative effect of other components in DHW? And how the authors exclude the possibility of combined toxicity of costunolide and berberine in the B+C mixture rather than synergistic effect?

We are interested in studying the anti-proliferative effect of other components in DHW. The composition of herbal medicines is very complex and consists of many (perhaps hundreds) ingredients, some of which contribute to its clinical effect. In this study, DHW is a traditional herbal medicine consisting of Coptidis Rhizoma and Aucklandia lappa Decne. It is well known that Berberine and Costunolide are the main bioactive components of Coptidis Rhizoma and Aucklandia lappa Decne. Therefore, our study began to focus on berberine and Costunolide. We do not rule out the possibility that other components in DHW may contribute to the anti-cancer effect of DHW, and are very interested in studying them in future.

We are careful about the possibility of combined toxicity of Costunolide and Berberine. As shown in Figure 1C, DHW extract inhibited the growth of SMMC-7721, HepG2, Hur7, and LM3 cells in a dose-and time-dependent manner, and these cells have different sensitivities against DHW extract. The effect of DHW on the QSG-7701 human hepatocytes was limited (Fig. 1B), indicating that the inhibition of DHW on the growth of various liver cancer cell lines should not be derived from cytotoxicity (line 217-219). On the other hand, previous studies suggested that the cytotoxicity of Berberine and Costunolide is limited. According to Wang N et al. the LD50 values of Berberine in mice was 713.57 mg/kg and the LD50 values of Berberine in 3T3-L1 cells was 41.76 mg/ml (Wang N et al. J Ethnopharmacol. 2015, 176:35-48). There are few studies on toxicity of Costunolide, 10-50 uM Contunolide is commonly used for cell signal transduction studies through cell culture（e.g. Kim DY et al. Int. J. Mol. Sci. 2019, 20:2926-2947).

3\. To confirm the DHW-regulated EGF signalling, it is more reasonable to rescue the EGFR expression rather than blocking it by inhibitor.

Ideally, we wish to rescue the inhibitory effect of DHW on cell proliferation through EGFR overexpression, thereby confirming EGF signaling regulated by DHW. However, this requires that EGFR expression can significantly promote the growth of liver cancer cells. Unfortunately, EGFR homeostasis is tightly controlled in cells. EGFR expression is necessary but not sufficient for cell growth. EGFR overexpression alone is not able to promote the proliferation of hepatoma cell or human hepatocytes such as QSG-7701. Therefore, we cannot perform the ideal experiment described above. We then used an alternative indirect approach: the EGFR inhibitor. Both DHW extract and EGFR inhibitor SC0186 significantly inhibited the growth of liver cancer cells (Figure 3D). However, DHW extract alone and the combination of DHW extract and SC0186 had similar inhibitory effects on the proliferation of PLC/PRF/5 cells (Figure 3D). The combination of the EGFR inhibitor SC0186 with DHW does not bring additional benefits. This shows that DHW extract and SC0186 act on the same signal pathway and the effects cannot be superimposed (line 296-303). Thus, this result indicates that DHW inhibits the proliferation of liver cancer cells by regulating EGF signaling.

4\. It is interesting to show that berberine promotes endocytosis while costunolide promotes EGFR ubiquitination. But how did the authors explain for Fig 4D that berberine seems increase the ubiquitin level of EGFR.
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